Checkpoint Therapeutics Inc
NASDAQ:CKPT 12:59:38 PM EDT
| Market Cap (Intraday) | 255.74M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $3.40 |
| 50-Day MA | $3.49 |
| 200-Day MA | $3.08 |
Checkpoint Therapeutics Inc Stock, NASDAQ:CKPT
2 Gansevoort Street, 9th floor, New York, New York 10014
United States of America
Phone: +1.781.652.4500
Number of Employees: 10
Description
Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Its product portfolio include CK-301, CK-101, CK-103, CK-302, and Anti-CAIX. The company was founded on November 10, 2014 and is headquartered in New York, NY.